Eleanor Bhatt

Eleanor Bhatt has been involved in the clinical development and evaluation of mRNA-4157 (V940) in the KEYNOTE-942 trial, which demonstrated 44% reduction in recurrence or death in high-risk resected melanoma when combined with pembrolizumab. Her research has characterized the immunological responses to mRNA-4157, including the induction of neoantigen-specific T cell responses across all evaluated patients. She has investigated biomarkers of response to the mRNA-4157/pembrolizumab combination. Her work is advancing mRNA neoantigen vaccine development into adjuvant treatment across multiple solid tumor types.